Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E3LA
|
|||
| Former ID |
DNC010025
|
|||
| Drug Name |
(R)-2-amino-3-(4-octylphenylamino)propan-1-ol
|
|||
| Synonyms |
CHEMBL572686; (R)-2-amino-3-(4-octylphenylamino)propan-1-ol; SCHEMBL1312243
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H30N2O
|
|||
| Canonical SMILES |
CCCCCCCCC1=CC=C(C=C1)NCC(CO)N
|
|||
| InChI |
1S/C17H30N2O/c1-2-3-4-5-6-7-8-15-9-11-17(12-10-15)19-13-16(18)14-20/h9-12,16,19-20H,2-8,13-14,18H2,1H3/t16-/m1/s1
|
|||
| InChIKey |
RCARSJSFSXRXLF-MRXNPFEDSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sphingosine kinase 2 (SPHK2) | Target Info | Inhibitor | [1] |
| BioCyc | Sphingosine and sphingosine-1-phosphate metabolism | |||
| KEGG Pathway | Sphingolipid metabolism | |||
| Metabolic pathways | ||||
| Calcium signaling pathway | ||||
| Sphingolipid signaling pathway | ||||
| VEGF signaling pathway | ||||
| Fc gamma R-mediated phagocytosis | ||||
| Tuberculosis | ||||
| Panther Pathway | Angiogenesis | |||
| VEGF signaling pathway | ||||
| Pathwhiz Pathway | Sphingolipid Metabolism | |||
| Pathway Interaction Database | IL12-mediated signaling events | |||
| Ceramide signaling pathway | ||||
| Sphingosine 1-phosphate (S1P) pathway | ||||
| Reactome | Sphingolipid de novo biosynthesis | |||
| WikiPathways | Signal Transduction of S1P Receptor | |||
| Sphingolipid Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Discovery of novel sphingosine kinase 1 inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6119-21. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.